New York State Common Retirement Fund Has $302,000 Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

New York State Common Retirement Fund grew its position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 12.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 15,248 shares of the company’s stock after purchasing an additional 1,680 shares during the period. New York State Common Retirement Fund’s holdings in Kiniksa Pharmaceuticals were worth $302,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Harbor Capital Advisors Inc. acquired a new position in shares of Kiniksa Pharmaceuticals in the 3rd quarter valued at approximately $2,438,000. AlphaCentric Advisors LLC acquired a new position in Kiniksa Pharmaceuticals in the 3rd quarter worth $287,000. Los Angeles Capital Management LLC increased its holdings in Kiniksa Pharmaceuticals by 26.3% during the 3rd quarter. Los Angeles Capital Management LLC now owns 100,001 shares of the company’s stock worth $2,499,000 after purchasing an additional 20,801 shares in the last quarter. GSA Capital Partners LLP bought a new stake in shares of Kiniksa Pharmaceuticals in the third quarter valued at about $268,000. Finally, Segall Bryant & Hamill LLC bought a new position in shares of Kiniksa Pharmaceuticals during the third quarter worth about $675,000. Institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Trading Down 0.6 %

Kiniksa Pharmaceuticals stock opened at $21.33 on Wednesday. Kiniksa Pharmaceuticals, Ltd. has a 12 month low of $16.56 and a 12 month high of $28.15. The company has a market capitalization of $1.54 billion, a price-to-earnings ratio of -152.35 and a beta of 0.32. The stock’s 50 day moving average is $19.68 and its 200-day moving average is $22.44.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its earnings results on Tuesday, February 25th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06). The company had revenue of $122.50 million for the quarter, compared to the consensus estimate of $123.42 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business’s revenue was up 46.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.35 earnings per share. As a group, equities research analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Wedbush restated an “outperform” rating and set a $34.00 target price on shares of Kiniksa Pharmaceuticals in a report on Tuesday, February 25th. JPMorgan Chase & Co. boosted their price target on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $36.60.

Insider Transactions at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 14,000 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $19.57, for a total transaction of $273,980.00. Following the sale, the chief operating officer now directly owns 81,975 shares of the company’s stock, valued at $1,604,250.75. The trade was a 14.59 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last quarter, insiders sold 29,123 shares of company stock valued at $553,204. Corporate insiders own 54.57% of the company’s stock.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.